ADVM Shares Outstanding History



Below is a table of the ADVM shares outstanding history going back to 7/31/2014:

Date ADVM Shares Outstanding
7/31/20142.08M
8/31/20142.23M
10/31/20142.25M
2/28/20152.52M
4/30/20152.55M
7/31/20152.57M
10/31/20152.58M
2/29/20162.69M
4/29/20162.71M
7/29/20164.13M
10/31/20164.17M
2/28/20174.21M
4/30/20174.29M
7/31/20174.33M
10/31/20174.50M
2/28/20186.22M
4/30/20186.23M
7/31/20186.27M
10/31/20186.29M
2/28/20196.32M
4/30/20196.34M
7/31/20196.45M
8/8/20191.77M
10/31/20196.46M
2/28/20207.97M
8/3/20208.07M
10/30/20209.75M
2/22/20219.78M
4/29/20219.79M
7/30/20219.81M
10/29/20219.82M
3/18/20229.88M
5/6/20229.88M
11/4/20229.97M
3/17/202310.06M
5/5/202310.06M
8/4/202310.10M
10/31/202310.10M
3/8/202420.75M

Also see: ADVM Market Cap History
ADVM YTD Return
ADVM Historical Shares Outstanding:
+27.06% CAGR
ADVM Historical Shares Outstanding: +27.06% CAGR

Mouse over chart for data details
7/31/2014 ...3/8/2024
Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a standard of care for ocular diseases. Co.'s main product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection. We show 39 historical shares outstanding datapoints in our coverage of ADVM's shares outstanding history.

Understanding the changing numbers of ADVM shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ADVM versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ADVM by allowing them to research ADVM shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ADVM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adverum Biotechnologies (ADVM) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ADXS Shares Outstanding History
ADYX Shares Outstanding History
AEMD Shares Outstanding History
AERI Shares Outstanding History
AEZS Shares Outstanding History
AFIB Shares Outstanding History
AGEN Shares Outstanding History
AGIO Shares Outstanding History
AGL Shares Outstanding History
AGLE Shares Outstanding History
More Healthcare companies »

 

ADVM Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.